FMP
GH Research PLC
GHRS
NASDAQ
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neurological disorders. GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland.
11.08 USD
-0.22 (-1.99%)
About
ceo
Dr. Theis Terwey M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.ghres.com
exchange
NASDAQ
Description
GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH001, an inhalable 5-MeO-DMT product candidate that has completed two Phase 1 clinical trials and Phase 1/2 clinical trial in patients with TRD. The company also develops GH002, an injectable 5-MeO-DMT product candidate; and GH003, an intranasal 5-MeO-DMT product candidate, which are in preclinical development trials with a focus on psychiatric and neur...
CIK
0001855129
ISIN
IE000GID8VI0
CUSIP
G3855L106
Address
28 Baggot Street Lower
Phone
353 1 437 8443
Country
IE
Employee
49
IPO Date
Jun 25, 2021
Summary
CIK
0001855129
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
G3855L106
ISIN
IE000GID8VI0
Country
IE
Price
11.08
Beta
0.84
Volume Avg.
131.62k
Market Cap
576.47M
Shares
-
52-Week
5.05-14.64
DCF
1.5
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-16.29
P/B
-
Website
https://www.ghres.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest GHRS News
It looks like there's no news available.
